ClouDr Group (9955) H1 2025 earnings summary

Executive summary

• Shifted from scale-led expansion to higher-quality, cash-generative growth, prioritizing AI-enabled SaaS and P2M while reducing lower-margin medical supplies and consumables.

• H1 revenue fell 58.0% YoY to RMB892.6 million as value-added sales declined; gross margin rose to 37.1%.

• Operating cash flow turned positive at RMB28.7 million, versus an outflow of RMB195.5 million in H1 2024; P2M revenue was RMB261.2 million and the business was profitable at June 30, 2025.

Financial highlights

• Gross profit was RMB331.0 million, down 24.3%; reported gross margin rose to 37.1% from 20.6%, while adjusted gross profit increased 1.9% to RMB445.3 million.

• Adjusted gross margin was 49.9%, excluding RMB114.3 million of inventory impairment tied to disposals and proposed disposals.

• IFRS net loss widened to RMB642.9 million from RMB118.9 million; operating loss was RMB588.0 million versus RMB102.9 million, reflecting disposal-related losses and a one-off provision.

• Adjusted net loss rose to RMB63.4 million from RMB32.9 million, excluding specified non-cash, financing-related, disposal and one-off items; adjusted net loss margin was 7.1%.

Outlook and guidance

• Priorities include growing hospital and pharmacy SaaS networks, expanding the proprietary P2M pipeline, investing in medical AI, growing patient and doctor users, and pursuing strategic partnerships and acquisitions.

• Iloprost Infusion for Injection is targeted for Greater Bay Area sales approval by end-September 2025; national CDE submission is planned by end-2025, conditional approval by June 2027 and launch by August 2027.

• Eight additional P2M products were in registration application or pre-launch in H1 2025; out-of-hospital strategy will focus on pharmacy network growth and improved P2M profitability.